These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Seroreactivity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease. Barta Z; Csípõ I; Szabó GG; Szegedi G World J Gastroenterol; 2003 Oct; 9(10):2308-12. PubMed ID: 14562398 [TBL] [Abstract][Full Text] [Related]
6. ASCA: genetic marker, predictor of disease, or marker of a response to an environmental antigen? Seibold F Gut; 2005 Sep; 54(9):1212-3. PubMed ID: 16099786 [No Abstract] [Full Text] [Related]
7. Anti-Saccharomyces cerevisiae (ASCA) and anti-neutrophil cytoplasmic (ANCA) antibodies are not increased in Takayasu arteritis. Ozbakir F; Ugurlu S; Celik AF; Seyahi E Acta Reumatol Port; 2011; 36(1):20-3. PubMed ID: 21483276 [TBL] [Abstract][Full Text] [Related]
8. Antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies in inflammatory bowel diseases. Kiliç ZM; Tunç B; Ayaz S; Filik L; Aktaş S; Parlak E; Ulker A Turk J Gastroenterol; 2004 Dec; 15(4):238-42. PubMed ID: 16249978 [TBL] [Abstract][Full Text] [Related]
9. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Amre DK; Lu SE; Costea F; Seidman EG Am J Gastroenterol; 2006 Mar; 101(3):645-52. PubMed ID: 16464223 [TBL] [Abstract][Full Text] [Related]
10. [Serological markers in inflammatory bowel disease: differences among populations and limitations of their application]. Barahona-Garrido J; Hernández-Calleros J; Sarti HM; Cabiedes J; Yamamoto-Furusho JK Gastroenterol Hepatol; 2009 May; 32(5):380-1. PubMed ID: 19457592 [No Abstract] [Full Text] [Related]
11. Clinical utility of serological markers in inflammatory bowel disease. Mokrowiecka A; Daniel P; Słomka M; Majak P; Malecka-Panas E Hepatogastroenterology; 2009; 56(89):162-6. PubMed ID: 19453050 [TBL] [Abstract][Full Text] [Related]
12. Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn's disease and ulcerative colitis: diagnostic value and correlation with disease phenotype. Zholudev A; Zurakowski D; Young W; Leichtner A; Bousvaros A Am J Gastroenterol; 2004 Nov; 99(11):2235-41. PubMed ID: 15555007 [TBL] [Abstract][Full Text] [Related]
14. The prevalence and diagnostic value of perinuclear antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in patients with inflammatory bowel disease in mainland China. Zhou F; Xia B; Wang F; Shrestha UK; Chen M; Wang H; Shi X; Chen Z; Li J Clin Chim Acta; 2010 Oct; 411(19-20):1461-5. PubMed ID: 20570669 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic precision of anti-Saccharomyces cerevisiae antibodies and perinuclear antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Reese GE; Constantinides VA; Simillis C; Darzi AW; Orchard TR; Fazio VW; Tekkis PP Am J Gastroenterol; 2006 Oct; 101(10):2410-22. PubMed ID: 16952282 [TBL] [Abstract][Full Text] [Related]
16. pANCA and ASCA in the diagnosis of different subtypes of inflammatory bowel disease. Mokrowiecka A; Gasiorowska A; Malecka-Panas E Hepatogastroenterology; 2007; 54(77):1443-8. PubMed ID: 17708273 [TBL] [Abstract][Full Text] [Related]
17. Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis. Davis MK; Andres JM; Jolley CD; Novak DA; Haafiz AB; González-Peralta RP J Pediatr Gastroenterol Nutr; 2007 Oct; 45(4):409-13. PubMed ID: 18030205 [TBL] [Abstract][Full Text] [Related]
18. [Interest of serologic markers in inflammatory bowel disease. About 105 cases]. Fekih M; Ben Hlima S; Zitouni M; Matri S; Boubaker J; Makni S; Azza F Tunis Med; 2007 Oct; 85(10):821-8. PubMed ID: 18236802 [TBL] [Abstract][Full Text] [Related]